A Phase II Trial Evaluating APX005M (a CD40 Agonistic Monoclonal Antibody) in Combination With Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcomas
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2019
Price : $35 *
At a glance
- Drugs APX 005M (Primary) ; Doxorubicin (Primary)
- Indications Liposarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 03 Apr 2019 Status changed from not yet recruiting to recruiting.
- 28 Feb 2019 Planned initiation date changed from 1 Dec 2018 to 1 Apr 2019.
- 20 Dec 2018 According to an Apexigen media release, the company has collaborated with Columbia University Irving Medical Center for the conduct of this trial.